{"title":"β-细辛酮通过激活PP2A和参与Akt/mTOR/Beclin-1通路保护PC12细胞对磷酸的保护作用","authors":"Li-Ping Huang, Xiaoqin Zhong, Yuanhang Xu, Minzhen Deng, Zhongliu Zhou","doi":"10.1177/09731296231168743","DOIUrl":null,"url":null,"abstract":"Background The aggregation of tau hyperphosphorylation (p-tau) into neurofibrillary tangles (NFT) is a hallmark in the histopathology of Alzheimer’s disease (AD). Our previous experiments found that β-asarone could prevent injury of PC12 cells induced by A 1–42, but could it fight cell damage of p-tau induced by okadaic acid (OA) is poorly understood. Objectives The emphasis of this study lies in β-asarone’s therapeutical effect on p-tau inhibition stimulated by OA. Materials and Methods 175 nmol OA was used to establish AD cells. Cell viability rate and cell toxicity were evaluated by the CCK-8 kit and LDH kit, respectively. The p-tau, Aβ42, β-secretase, and protein phosphatase 2A (PP2A) were examined by ELISA. Proteins closely related to the pathogenesis of AD are involved p-tau, Beclin-1, p-Akt, and p-mTOR were analyzed by western-blotting and immunofluorescence detection. Results The results revealed that β-asarone enhanced cell viability induced by OA in a dose-dependent manner. Moreover, compared to the OA model, p-tau, Aβ42, β-secretase, and Beclin-1 were reduced, while PP2A, p-Akt, and p-mTOR increased after treatment with β-asarone. Conclusion All data suggested that β-asarone decreased p-tau, Aβ42, and β-secretase levels, and activated PP2A levels by inhibiting Beclin-1-dependent autophagy in OA model cells, involving Akt/mTOR/Beclin-1 pathway.","PeriodicalId":19895,"journal":{"name":"Pharmacognosy Magazine","volume":"19 1","pages":"727 - 735"},"PeriodicalIF":0.6000,"publicationDate":"2023-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"β-asarone Protects p-tau from Okadaic Acid in PC12 Cells by Activating PP2A and Involving Akt/mTOR/Beclin-1 Pathway\",\"authors\":\"Li-Ping Huang, Xiaoqin Zhong, Yuanhang Xu, Minzhen Deng, Zhongliu Zhou\",\"doi\":\"10.1177/09731296231168743\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background The aggregation of tau hyperphosphorylation (p-tau) into neurofibrillary tangles (NFT) is a hallmark in the histopathology of Alzheimer’s disease (AD). Our previous experiments found that β-asarone could prevent injury of PC12 cells induced by A 1–42, but could it fight cell damage of p-tau induced by okadaic acid (OA) is poorly understood. Objectives The emphasis of this study lies in β-asarone’s therapeutical effect on p-tau inhibition stimulated by OA. Materials and Methods 175 nmol OA was used to establish AD cells. Cell viability rate and cell toxicity were evaluated by the CCK-8 kit and LDH kit, respectively. The p-tau, Aβ42, β-secretase, and protein phosphatase 2A (PP2A) were examined by ELISA. Proteins closely related to the pathogenesis of AD are involved p-tau, Beclin-1, p-Akt, and p-mTOR were analyzed by western-blotting and immunofluorescence detection. Results The results revealed that β-asarone enhanced cell viability induced by OA in a dose-dependent manner. Moreover, compared to the OA model, p-tau, Aβ42, β-secretase, and Beclin-1 were reduced, while PP2A, p-Akt, and p-mTOR increased after treatment with β-asarone. Conclusion All data suggested that β-asarone decreased p-tau, Aβ42, and β-secretase levels, and activated PP2A levels by inhibiting Beclin-1-dependent autophagy in OA model cells, involving Akt/mTOR/Beclin-1 pathway.\",\"PeriodicalId\":19895,\"journal\":{\"name\":\"Pharmacognosy Magazine\",\"volume\":\"19 1\",\"pages\":\"727 - 735\"},\"PeriodicalIF\":0.6000,\"publicationDate\":\"2023-06-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmacognosy Magazine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/09731296231168743\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacognosy Magazine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/09731296231168743","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
β-asarone Protects p-tau from Okadaic Acid in PC12 Cells by Activating PP2A and Involving Akt/mTOR/Beclin-1 Pathway
Background The aggregation of tau hyperphosphorylation (p-tau) into neurofibrillary tangles (NFT) is a hallmark in the histopathology of Alzheimer’s disease (AD). Our previous experiments found that β-asarone could prevent injury of PC12 cells induced by A 1–42, but could it fight cell damage of p-tau induced by okadaic acid (OA) is poorly understood. Objectives The emphasis of this study lies in β-asarone’s therapeutical effect on p-tau inhibition stimulated by OA. Materials and Methods 175 nmol OA was used to establish AD cells. Cell viability rate and cell toxicity were evaluated by the CCK-8 kit and LDH kit, respectively. The p-tau, Aβ42, β-secretase, and protein phosphatase 2A (PP2A) were examined by ELISA. Proteins closely related to the pathogenesis of AD are involved p-tau, Beclin-1, p-Akt, and p-mTOR were analyzed by western-blotting and immunofluorescence detection. Results The results revealed that β-asarone enhanced cell viability induced by OA in a dose-dependent manner. Moreover, compared to the OA model, p-tau, Aβ42, β-secretase, and Beclin-1 were reduced, while PP2A, p-Akt, and p-mTOR increased after treatment with β-asarone. Conclusion All data suggested that β-asarone decreased p-tau, Aβ42, and β-secretase levels, and activated PP2A levels by inhibiting Beclin-1-dependent autophagy in OA model cells, involving Akt/mTOR/Beclin-1 pathway.